shadow_tr
/Users/cclarks/Desktop/Dept Website/Faculty/faces/jim

James W. Fisher, PhD

(University of Louisville School of Medicine, 1958)


 

Professor Emeritis



 

Research Interests

Hematopharmacology; endocrine pharmacology; renal pharmacology; hormones and erythropoietin; anemia of end-stage renal disease; adenosine; cyclic nucleotides; nitric oxide and C kinase and erythropoietin production; eicosanoids and erythropoiesis

 

Academic Training

BS in Chemistry - University of South Carolina, Columbia, SC, 1947
PhD in Pharmacology - University of Louisville School of Medicine, Louisville KY, 1958
Instructor-Professor, Dept of Pharmacology, Univ of Tennessee Medical Units, Memphis, TN, 1958-68
Professor and Chairman, Dept of Pharmacology, Tulane Univ School of Medicine, New Orleans, LA, 1968-96
Regents Professor, Dept of Pharmacology, Tulane Univ School of Medicine, New Orleans, LA, 1987-96

 

Honors

USPHS, Research Career Development Award, 1960-65
Purkinje Medal, Czech Medical Society, 1975
Golden Sovereign Award, University of Louisville, 1976
Regents Endowed Professorship in Pharmacology, Tulane University, 1987
James W. Fisher Lectureship in Pharmacology, Tulane University Medical School, established 1991
ASPET Award, Experimental Therapeutics 1992
Member of of Alpha Omega Alpha (Distinguished Faculty) 1992
Owl Club Award for Medical Student Teaching, 1996
Alumni Award, University of Louisville School of Medicine, 1999

 

Pharmaceutical Industry Positions

Developmental Chemist, Pharmaceutical Development Dept, Armour Pharmaceutical Co., Chicago, IL, 1950-53
Pharmacologist, Dept of Pharmacology, Lloyd Bros, Inc. Pharmaceutical Research Labs, Cincinnati, OH, 1954-56

 

Research Interests

The primary research interests of my laboratory involve signal transduction pathways in hypoxic regulation of erythropoietin (Epo) production. Our laboratory is focusing on the role of adenosine, which is elevated in kidney tissue during hypoxia, in the regulation of kidney production of Epo. Adenosine receptor activation through both cyclic nucleotide and kinase C pathways may be involved with inducing an hypoxia-inducible element in the erythropoietin gene which expresses Epo mRNA. A phosphorylation event which may be involved with binding of an hypoxia-inducible factor to DNA may be important in the transcription of Epo mRNA. In addition, nitric oxide and guanylate cyclase activation of the G kinase pathway may also be important in regulating transcriptional events in Epo mRNA production. The techniques ongoing in my laboratory involve hepatocellular carcinoma (Hep 3B, Hep 3G) cell lines which spontaneously produce Epo; a polymerase chain reaction (PCR) method for determining mRNA for Epo; an isolated perfused rat kidney in which Epo production in response to hypoxia can be studied; and a polycythemic mouse model induced by hypoxia are all available to study hypoxic regulation of Epo production.

 

Address

Department of Pharmacology SL83, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112-2699. tel 504-988-5444; fax 504-988-5283; e-mail: jfisher@tulane.edu


 

1430 Tulane Avenue, SL-83, New Orleans, LA 70112 504-988-5444 cclarks@tulane.edu